Resumen de acción LJPC
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de La Jolla Pharmaceutical Company
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.22 |
| 52 Week High | US$6.24 |
| 52 Week Low | US$3.07 |
| Beta | 2.41 |
| 1 Month Change | 0.49% |
| 3 Month Change | 65.87% |
| 1 Year Change | 59.08% |
| 3 Year Change | -36.92% |
| 5 Year Change | -81.03% |
| Change since IPO | -100.00% |
Noticias y actualizaciones recientes
Recent updates
Innoviva to acquire La Jolla Pharma for $149M including debt
Jul 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative
Nov 11
Our Take On La Jolla Pharmaceutical Company
Jul 02La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue
May 07La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares
Mar 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Feb 11Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
Jan 16La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION
Jan 12Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?
Jan 05Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?
Dec 09La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue
Nov 09Rentabilidad de los accionistas
| LJPC | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.5% | 0.5% | -0.7% |
| 1Y | 59.1% | 1.2% | 22.8% |
Rentabilidad vs. Industria: LJPC superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: LJPC superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| LJPC volatility | |
|---|---|
| LJPC Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de LJPC ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LJPC ha aumentado de 14% a 24% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 61 | Larry Edwards | www.lajollapharmaceutical.com |
Resumen de fundamentos de La Jolla Pharmaceutical Company
| Estadísticas fundamentales de LJPC | |
|---|---|
| Capitalización bursátil | US$155.11m |
| Beneficios(TTM) | US$3.97m |
| Ingresos (TTM) | US$46.49m |
39.1x
Ratio precio-beneficio (PE)3.3x
Ratio precio-ventas (PS)¿Está LJPC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LJPC | |
|---|---|
| Ingresos | US$46.49m |
| Coste de los ingresos | US$8.87m |
| Beneficio bruto | US$37.62m |
| Otros gastos | US$33.65m |
| Beneficios | US$3.97m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.16 |
| Margen bruto | 80.92% |
| Margen de beneficio neto | 8.54% |
| Ratio deuda/patrimonio | -179.3% |
¿Cómo se ha desempeñado LJPC a largo plazo?
Ver rendimiento histórico y comparativa